Thank you to all our Partner organisations:
Boehringer Ingelheim has 100 years of heritage in respiratory disease.
Since 1921 we have emerged as a leader in this disease area, having developed and launched treatments for a range of respiratory conditions including lung cancer, asthma, chronic obstructive pulmonary disease (COPD), treatment of adults with idiopathic pulmonary fibrosis (IPF) and other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.
Our continued focus is on improving the life of patients suffering from debilitating respiratory diseases.
PC-GB-105963 Date of preparation; November 2021
Boehringer Ingelheim (BI) has provided financial support to ARNS as a partnership for 2023. The funding enabled ARNS to provide ongoing education and development for respiratory nurses. BI has had no input into ARNS activities other than an exhibition stand and a symposium slot at the annual conference.